

8-10-01

A

Please type a plus sign (+) inside this box ☐

Attorney Docket No. P0718P2C1D1C1


PATENT

Box See

08/08/01



J1025 U.S. PTO

CERTIFICATION UNDER 37 CFR 1.10	
EL 809447945 US: Express Mail Number	August 8, 2001: Date of Deposit
I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PATENT APPLICATION, Commissioner of Patents and Trademarks, Washington, DC 20231.	
 Glory L. Tabuena	

J1025 U.S. PTO

09/925179



08/08/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION

Commissioner of Patents and Trademarks

Washington, DC 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Paula M. Jardieu, San Mateo, California

Leonard G. Presta, San Francisco, California

Title: **ANTI-IgE ANTIBODIES**

1. Type of Application

☐ This application is for an original, non-provisional application.

☐ This is a non-provisional application claiming priority to provisional application no. __, filed __, the entire disclosure of which is hereby incorporated by reference.

☒ This is a ☐ continuation-in-part ☒ continuation ☐ divisional application claiming priority to application Serial No. 08/466,163, filed June 6, 1995, which is a divisional of Serial No. 08/405,617, filed March 15, 1995, which is a continuation of Serial No. 08/185,899, filed on January 26, 1994, now abandoned, which is a 35 USC 371 of PCT/US92/06860, filed on August 14, 1992, which is a continuation-in-part of both Serial Nos. 07/879,495, filed on May 7, 1992, now abandoned and Serial No. 07/744,768, filed on August 14, 1991, now abandoned, the entire disclosure of which is hereby incorporated by reference.

2. Papers Enclosed Which are Required for Filing Date Under 37 CFR 1.53(b) (Non-provisional)

61 pages of specification

6 pages of claims

#95174

1 page(s) of abstract
7 sheet(s) of drawings
[X] formal [] informal

3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)
___ An executed declaration of the inventor(s) [] is enclosed [] will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)
X A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

(for Cont./Div. where inventor(s) being deleted)
___ A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

4. Assignment

(for new and CIP applications)
___ An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.

(for cont./div.)
X The prior application is assigned of record to Genentech, Inc.

5. Amendments (for continuation and divisional applications)

X Cancel in this application original claims 2-57 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

X A Preliminary Amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119

___ Amend the specification by inserting before the first line the sentence:

--This is a

___ non-provisional application
___ continuation
___ divisional
___ continuation-in-part

of co-pending application(s)

- _____ Serial No. _ filed on __, which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120. --
- _____ International Application _ filed on __ which designated the U.S., which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120.--
- _____ provisional application No. _ filed __, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119.--

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$710.00
Total Claims	21	- 20 =	1	X \$18.00	\$18.00
Independent Claims	1	- 3 =	0	X \$80.00	\$0.00
Multiple dependent claim(s), if any				+ \$270.00	\$0.00
Filing Fee Calculation					\$728.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$728.00. **A duplicate copy of this transmittal is enclosed.**

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 C.F.R. §§1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

9. Additional Papers Enclosed

- ☐ Information Disclosure Statement (37 C.F.R. §1.98) w/ PTO-1449 and citations
- ☒ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☒ Other: Formal Drawing sheets (Figs. 1-5c)

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

*[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

_____ A petition, fee and/or response has been filed to extend the term in
the pending prior application until
_____ A copy of the petition for extension of time in the *prior* application
is attached.

11. Correspondence Address:

X Address all future communications to:

Attn: Craig G. Svoboda

Respectfully submitted,
GENENTECH, INC.

By: Craig G. Svoboda
Craig G. Svoboda
Reg. No. 39,044
Telephone No. (650) 225-1489


Date: August 8th, 2001



09157

PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of</p> <p>Jardieu <i>et al.</i></p> <p>Serial No.: not assigned</p> <p>Filed: herewith</p> <p>For: <i>Anti-IgE Antibodies</i></p>	<p>Group Art Unit: not assigned</p> <p>Examiner: not assigned</p> <hr/> <p>CERTIFICATION UNDER 37 CFR 1.10</p> <p>EL 809447945 US. Express Mail Number</p> <p><u>August 8, 2001</u>: Date of Deposit</p> <p>I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PATENT APPLICATION, Commissioner of Patents and Trademarks, Washington, DC 20231.</p> <p> Glory L. Tabuena</p>
--	---

CERTIFICATE RE: SEQUENCE LISTING
RESPONSE UNDER 37 CFR § 1.821(f) and (g)

Box PATENT APPLICATION
 Commissioner of Patents and Trademarks
 Washington, DC 20231

Sir:

Applicants hereby state that the Sequence Listing submitted herewith is submitted in paper copy and a computer-readable diskette, and that the information recorded in computer readable form is identical to the written sequence listing. We further state that this submission includes no new matter.

Respectfully submitted,

GENENTECH, INC.

By:



Craig G. Svoboda

Reg. No. 39,044

Telephone No. (650) 225-1489



09157

PATENT TRADEMARK OFFICE